Please assess the completion status of the following clinical trial:

Trial Title: A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy confirmed diagnosis of non-alcoholic steatohepatitis (within past 12 months)~* Ages 10 yrs and older~* Must swallow tablets on a regular basis~* ALT level \>60 iu/L~Exclusion Criteria:~* Subjects with known hypersensitivity to cysteamine~* History, currently or within the past 3 months, of the following conditions:~* Pancreatitis~* Inflammatory bowel disease~* Malabsorption~* Unstable heart disease, e.g., myocardial infarction, heart failure, arrhythmias.~* Unstable diabetes mellitus~* Any bleeding disorder.~* Zollinger-Ellison syndrome~* Malignant disease~* Subjects whom maybe pregnant or have health issues that make it unsafe for them participate, or whose concomitant medical problems preclude them from committing to the study schedule.~* No specific NASH medical therapy for 3 months such as vitamin E, s-adenosyl methionine or metformin or other NAFLD study drugs.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cystagon-EC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).